Cabozantinib (Cabometyx®) as monotherapy for the treatment of locally advanced or metastatic differentiated thyroid carcinoma (DTC). Update June 2022

Rothschedl, E. and Wolf, S. (2022): Cabozantinib (Cabometyx®) as monotherapy for the treatment of locally advanced or metastatic differentiated thyroid carcinoma (DTC). Update June 2022. Oncology Fact Sheet Nr. 87.

[thumbnail of Oncology Fact Sheet Nr.87_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
98kB

Item Type:	Horizon Scanning of Medicines
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WK Endocrine system > WK 200-300 Thyroid gland. Parathyroid gland
Language:	English
Series Name:	Oncology Fact Sheet Nr. 87
Deposited on:	25 Apr 2022 14:30
Last Modified:	10 Jul 2025 11:33

Repository Staff Only: item control page